Contrasting of Audentes Therapeutics Inc. (BOLD) and Nabriva Therapeutics plc (NASDAQ:NBRV)

This is a contrast between Audentes Therapeutics Inc. (NASDAQ:BOLD) and Nabriva Therapeutics plc (NASDAQ:NBRV) based on their analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership. The two companies are Biotechnology and they also compete with each other.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Audentes Therapeutics Inc. N/A 0.00 152.64M -3.79 0.00
Nabriva Therapeutics plc 3.81M 38.30 121.66M -2.16 0.00

We can see in table 1 the earnings per share, top-line revenue and valuation of Audentes Therapeutics Inc. and Nabriva Therapeutics plc.


Table 2 shows us Audentes Therapeutics Inc. and Nabriva Therapeutics plc’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Audentes Therapeutics Inc. 0.00% -40.8% -37.4%
Nabriva Therapeutics plc -3,193.18% 0% 0%


Audentes Therapeutics Inc. has a Current Ratio of 14.3 and a Quick Ratio of 14.3. Competitively, Nabriva Therapeutics plc’s Current Ratio is 5.6 and has 5.6 Quick Ratio. Audentes Therapeutics Inc.’s better ability to pay short and long-term obligations than Nabriva Therapeutics plc.

Analyst Ratings

Ratings and Recommendations for Audentes Therapeutics Inc. and Nabriva Therapeutics plc can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Audentes Therapeutics Inc. 0 0 1 3.00
Nabriva Therapeutics plc 0 0 0 0.00

Audentes Therapeutics Inc. has a consensus price target of $48, and a 28.76% upside potential.

Institutional & Insider Ownership

Institutional investors held 0% of Audentes Therapeutics Inc. shares and 53% of Nabriva Therapeutics plc shares. 1.3% are Audentes Therapeutics Inc.’s share held by insiders. Competitively, Nabriva Therapeutics plc has 0.1% of it’s share held by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Audentes Therapeutics Inc. 1.16% -5.46% 61.44% 59.29% 9.29% 79.32%
Nabriva Therapeutics plc 19.57% 5.36% 35.47% 27.31% -44.78% 88.36%

For the past year Audentes Therapeutics Inc. has weaker performance than Nabriva Therapeutics plc


Nabriva Therapeutics plc beats Audentes Therapeutics Inc. on 7 of the 10 factors.

Audentes Therapeutics, Inc., a biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects in the United States. The company is developing AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT982 for the treatment of pompe disease; and AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. Audentes Therapeutics, Inc. has a collaboration with the University of Pennsylvania for the treatment of Crigler-Najjar. The company was founded in 2012 and is headquartered in San Francisco, California.

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of novel antibiotics to treat serious bacterial infections with a focus on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, a novel semi-synthetic pleuromutilin antibiotic for systemic administration in humans. The companyÂ’s product, lefamulin is being studied in two registrational Phase 3 clinical trials in patients with moderate to severe community-acquired bacterial pneumonia. It is also developing lefamulin that has completed Phase 2 clinical trial for the treatment of acute bacterial skin and skin structure infections, as well as in preclinical studies for antibacterial activity against various gram-positive bacteria, gram-negative bacteria, and atypical bacteria, including multi-drug resistant strains. In addition, the company is developing BC-7013, a topical pleuromutilin product candidate, which has completed a Phase 1 clinical trial for the treatment of various gram-positive infections, including uncomplicated skin and skin structure infections. Nabriva Therapeutics plc was founded in 2006 and is based in Dublin, Ireland.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.